Exhibit 99.2
Arcadia Biosciences, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
(In thousands, except share data and per share data)
|
|
Three Months Ended March 31, |
|
|||||
|
|
|
2023 |
|
|
|
2022 |
|
Revenues: |
|
|
|
|
|
|
||
Product |
|
$ |
1,509 |
|
|
$ |
3,170 |
|
Royalty |
|
|
— |
|
|
|
50 |
|
Total revenues |
|
|
1,509 |
|
|
|
3,220 |
|
Operating expenses (income): |
|
|
|
|
|
|
||
Cost of revenues |
|
|
825 |
|
|
|
3,458 |
|
Research and development |
|
|
359 |
|
|
|
395 |
|
Change in fair value of contingent consideration |
|
|
— |
|
|
|
(31 |
) |
Gain on sale of property and equipment |
|
|
(19 |
) |
|
|
(328 |
) |
Selling, general and administrative |
|
|
4,392 |
|
|
|
4,349 |
|
Total operating expenses |
|
|
5,557 |
|
|
|
7,843 |
|
Loss from operations |
|
|
(4,048 |
) |
|
|
(4,623 |
) |
# # #
1